UCB Chooses Veeva Vault CRM for Global Customer Engagement

November 4, 2026, 13:03Source: PR Newswire

UCB has committed to adopting Veeva Vault CRM, an agentic customer engagement platform designed for the life sciences industry. Veeva Systems said the platform will provide UCB with technology to support its commercial strategy and unified engagement worldwide.

Key points

UCB has committed to adopting Veeva Vault CRM.
Vault CRM is part of Veeva's Vault CRM Suite for agentic commercial activities.
The platform includes specialized artificial intelligence for life sciences.
Veeva says agentic call reporting can reveal previously hidden treatment barriers.
Veeva has more than 1,500 customers.

UCB expands its partnership with Veeva

Veeva Systems announced the agreement on 4 November 2026. UCB will use Vault CRM as the technology foundation for its commercial operations, according to the company.

Edwin Erckens, UCB's director of digital technologies, said the adoption would strengthen the companies' strategic partnership. He said UCB and Veeva share a commitment to customer success, and that Vault CRM would give UCB the technology base needed to optimize execution of its commercial strategy.

Chris Moore, president of Veeva Europe, said Vault CRM would provide UCB with a stable, scalable technology infrastructure designed to support its commercial strategy over time. Veeva said it will work alongside UCB as the company carries out that strategy.

A CRM platform built for life sciences

Vault CRM is part of the Vault CRM Suite, which Veeva describes as a technology platform for agentic commercial activities. The CRM platform includes specialized artificial intelligence for the life sciences sector.

According to Veeva, that technology is intended to accelerate product launches and improve the customer experience. The announcement does not provide a launch date for UCB's adoption, or details about the scope and timing of its deployment.

Veeva also highlighted agentic call reporting in Vault CRM. The tool generates evidence-based commercial data that can reveal previously hidden barriers to treatment. The company presented this capability as a way to help commercial teams identify obstacles in the treatment journey through data from their interactions.

What the agreement means for the companies

For UCB, the agreement places customer engagement, artificial intelligence and commercial data within a single Veeva platform. The stated goal is unified engagement at global scale, although the announcement does not describe specific performance targets or the business areas UCB will migrate first.

For Veeva, the deal adds UCB to the companies using its cloud platform for the life sciences sector. Veeva says its platform includes applications, agents, data and consulting services, and has more than 1,500 customers, including major global biopharmaceutical companies and emerging biotech firms.

The expected benefits described in the announcement are forward-looking statements from Veeva. The company cautioned that actual results could differ materially from those statements and said it is not required to update them.